after 27 years in the metrodome, the gophers, back outdoors, at tcf bank stadium. last week, in a win over air force. right now, need to come up with something on third down and six, to keep the chains moving. trailing 14-0. weber rolling out. and he's going to throw deep for decker. what a grab. touchdown, minnesota. decker, shaken up as he got hammered after a beautiful catch. sean cattouse, with a great hit for cal. >> bob: what a play decker made. he knew his team needed a spark. he said, i'm going to go up and take the hit. >> chris: takes a shot. that's a good play by cattouse. but decker with the strong hands. and they hit him on the up. and cattouse, known for a big hitter. >> dave: he got a foot down. but it wasn't in the end zone. but where was the ball when he got hit? >> chris: to me, it looked like the ball had crossed. that was a good adjustment by weber and decker. an official review. we'll have the answer in a second. i love the adjustment. that comes from guys being roommates and knowing your receiver. he saw the outcut was taken away. then, he tur

cycle, some names like webster, like comerica, a bigger cap name, names like historia in new york, tcf out of minneapolis, i have about 80 names in the poif portfolio. so this is not a one-trick pony. i'm trying to give the refer a broad exposure to the industry. >> paul: do you personally own any of the stocks you mentioned? >> i certainly do through the funds, ask that's the way i've done it for a long time and plan to continue to do so. >> paul: so indirectly you do own them? >> yes, absolutely. >> paul: until today we saw quite a big runup in the financial sector with the s&p financials up more than 130% since march. do you think that rally is over or is this just a temporary pause? >> people always argue the stocks are ahead of the fundamentals, the fundamentals are ahead of the stocks. what i'm fgsing on is that we have an environment -- focusing on is that we are an environment where the fundamentals will be getting better over the next three to five years and you want to balance in the group. so today is one group out of the many and it doesn't matter, the question is do you wa

lifecycle evin works bter and now you start to strategizing by the tcf variant, this is data from therns out all three groups regardless of the genomic type so what is the added value for the testing in order to target the intervention i would say that among that this point in time. and the data from the behavioral literature is also limited and trying to use martyrs' for the sensation. this was evidence based view from the group last year that shows that a strategy to increase sensation based on a number of markers including genetic susceptibility at least as of last year we can make no statements about the effectiveness of the medical risk assessment as smoking cessation. so we still have a long way to go. in the last two minutes i would like to summarize t liver patients and recommendations in the panel and this was a panel that last year from the list of names you can see there is a number of people from the various companies from academia, nih, a cdc as well as and that as i said is available in the august issue of genetics and medicine. so the first recommendation the group made